Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CLN-418 in Advanced Solid Tumors
NCT05306444Phase 1Completed
- Sponsor
- Harbour BioMed
- Start
- May 2022
- Primary completion
- Aug 2024
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 1, open-label trial of CLN-418 in solid tumor (advanced stage), non-small cell lung cancer (NSCLC) and triple-negative breast cancer (TNBC) (2 arms), sponsored by Harbour BioMed. Primary endpoint: Proportion of subjects with dose-limiting toxicity. Started May 2022; status: completed.
02
Drugs
CLN-418
03
Conditions
solid tumor (advanced stage)non-small cell lung cancer (NSCLC)triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT05306444.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05306444.